Acorda Therapeutics To Provide Update On Clinical Development Pipeline At Upcoming R&D Day

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a Research and Development (R&D) Day for the investment community on Tuesday, November 5, 2013 from 9:00 a.m. to 12:00 p.m. at Alexandria Center for Life Sciences in New York City (450 East 29 th Street at First Avenue).

Members of Acorda’s management team, including President and CEO Ron Cohen, M.D., Chief Scientific Officer Andrew Blight, Ph.D., Chief Medical Officer Enrique Carrazana., M.D., and VP, Research and Development Anthony Caggiano, M.D., Ph.D., will review Acorda’s six clinical-stage programs. Presentations will include development programs in post-stroke deficits, cluster seizures, heart failure, neuropathic pain, multiple sclerosis and spinal cord injury.

Independent experts in the fields of heart failure, epilepsy, post stroke deficits and remyelination will provide their perspectives on disease state and current standards of care in their respective therapeutic area.

A live audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com or available via the following link prior to the start of the event:

http://www.media-server.com/m/p/ic98q9dq

The webcast of the presentation and copies of the slideshow will be available after the event by accessing the Investor section of www.acorda.com.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological conditions.

Acorda markets three FDA-approved therapies including: AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and QUTENZA® (capsaicin) 8% Patch, for the management of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda.

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Acorda Stiff-Arms Investor's Demand for Sale

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe